As we delve ever deeper into the complexity of disease, RNA-Sequencing has emerged as a fundamental tool in the arsenal of researchers. As we delve ever deeper into the complexity of disease, RNA-Sequencing has emerged as a fundamental tool in the arsenal of researchers.
Brian Haynes (Asuragen) speaks to Jason Green (Program Director, Hanson Wade) regarding RNA-Sequencing, ahead of the upcoming RNA-Seq 2014, June 17th-19th, Boston, MA
For details about the meeting, and more industry content related to RNA-Sequencing, please visit www.rna-seqsummit.com
What initially attracted you to RNA-Seq? I started using RNA-Seq during my doctoral studies in the early phase of a project after having started out with microarrays. The organism I was studying at the time was the pathogenic basidiomycete, Cryptococcus neoformans. RNA-Seq was a perfect fit for this project given the early draft stages of the cryptococcal genome annotation. What attracted me at the time and what still attracts me is that, unlike microarrays, with RNA-Seq you can actually see what you are measuring…